APA (7th ed.) Citation

Tran, B., Millward, M., Lemech, C., Frentzas, S., Day, D., Latifi, A., . . . Galkin, A. (2023). 1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. Annals of Oncology, 34, S635. https://doi.org/10.1016/j.annonc.2023.09.2186

Chicago Style (17th ed.) Citation

Tran, B., et al. "1047P AXA-042, a Systemically Administered TLR2/6 Agonist, Demonstrates Target Engagement and TLR Pathway Activation in Patients with Advanced Solid Tumors." Annals of Oncology 34 (2023): S635. https://doi.org/10.1016/j.annonc.2023.09.2186.

MLA (9th ed.) Citation

Tran, B., et al. "1047P AXA-042, a Systemically Administered TLR2/6 Agonist, Demonstrates Target Engagement and TLR Pathway Activation in Patients with Advanced Solid Tumors." Annals of Oncology, vol. 34, 2023, p. S635, https://doi.org/10.1016/j.annonc.2023.09.2186.